KDNY News and Press, Chinook Therapeutics Inc Com From 06/21/23

NEW YORK, NY / ACCESSWIRE / June 21, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NASDAQ:KD...

2023-06-20 09:33:57 ET If you're looking for stocks that can make dramatic moves to the upside in a short amount of time, the biopharmaceutical industry has you covered. Over the past month, shares of Chinook Therapeutics (NASDAQ: KDNY) and Vera Therapeutics (NASDAQ: VERA) h...

CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 days Pharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosing ...

NEW YORK, NY / ACCESSWIRE / June 16, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Eneti Inc. (NYSE:NETI)'s sale to Ca...

NEW YORK, NY / ACCESSWIRE / June 15, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Focus Financial Partners Inc. (NASDAQ...

NEW YORK, NY / ACCESSWIRE / June 13, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Bunge Limited (NYSE:BG)'s merger wi...

2023-06-12 16:13:12 ET Summary Novartis announced the acquisition of Chinook Therapeutics for $3.5 billion, boosting its pipeline and expanding into the kidney disease market. The deal can be paid for with around three months' worth of Novartis' free cash generation, and the compa...

Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2 Zigakibart is well-tolerated, wit...

2023-06-12 15:26:54 ET Short seller Muddy Waters still doesn't expect that Chinook Therapeutics ( NASDAQ: KDNY ) lead drug will ever be sold despite Novartis' ( NYSE: NVS ) agreement to purchas e the company for $3.2 billion . Chinook shares skyrocketed 58% on the de...

Chinook Therapeutics, Inc. (NASDAQ: KDNY) is one of today's top gainers. The company's shares are currently up 58.38% on the day to $37.99. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines fo...